StockData
Addex Therapeutics Ltd. logo

Addex Therapeutics Ltd. (ADXN) stock

ADXNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on May 15, 2026Score 0/30
$3.50−0.33 (-8.62%)

Close on Nov 17, 2026Market cap $71.86KP/E –Yield –

Addex Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was CHF 671.65K, down 21.4% from the year before. The highest annual figure on record is CHF 12.84M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 671.65K-21.4%
FY2024Dec 31, 2024CHF 854.31K-28.0%
FY2023Dec 31, 2023CHF 1.19M-85.6%
FY2022Dec 31, 2022CHF 8.24M-35.8%
FY2021Dec 31, 2021CHF 12.84M+23.8%
FY2020Dec 31, 2020CHF 10.37M-16.7%
FY2019Dec 31, 2019CHF 12.45M+153.2%
FY2018Dec 31, 2018CHF 4.92M+87.1%
FY2017Dec 31, 2017CHF 2.63M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026CHF 37.99K-99.3%
Q2 FY2025Jun 30, 2025CHF 234.45K-93.7%
Q2 FY2024Jun 30, 2024CHF 339.32K–
Q2 FY2023Jun 30, 2023CHF 1.88M–
Q2 FY2022Jun 30, 2022CHF 5.75M–
Q2 FY2021Jun 30, 2021CHF 3.73M–

More Addex Therapeutics figures

See a number that looks wrong?